Inventor · disambiguated record
Boro Dropulic
Also filed as: DROPULIC BORO
49 granted patents·30 pending applications·455 citations·filing 1996–2025
98Inventor score
Files withLENTIGEN TECH INC47UNIV JOHNS HOPKINS MED9VIRXSYS CORP7DROPULIC BORO4LENTIGENTECHNOLOGY INC3
Top patents by PatentIndex Score
79 records- 0197US10844128B2Compositions and methods for treating cancer with anti-CD123 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Nov 24, 2020·20 cites·11 claims
- 0297US10442867B2Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Oct 15, 2019·17 cites·7 claims
- 0397US10428141B2Compositions and methods for treating cancer with anti-ROR1 immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Oct 1, 2019·15 cites·13 claims
- 0496US11242389B2Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapyLENTIGEN TECH INC·Filed 2020·Granted Feb 8, 2022·5 cites·20 claims
- 0596US10183993B2Compositions and methods for treating cancer with anti-mesothelin immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Jan 22, 2019·11 cites·27 claims
- 0695US11208455B2Compositions and methods for treating cancer with DuoCARsLENTIGEN TECH INC·Filed 2019·Granted Dec 28, 2021·6 cites·8 claims
- 0795US10689431B2Compositions and methods for treating cancer with DuoCARsLENTIGEN TECH INC·Filed 2018·Granted Jun 23, 2020·8 cites·9 claims
- 0895US10543263B2Compositions and methods for treating cancer with anti-CD22 immunotherapyLENTIGENTECHNOLOGY INC·Filed 2018·Granted Jan 28, 2020·14 cites·12 claims
- 0995US10501539B2Compositions and methods for treating cancer with anti-CD19 immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Dec 10, 2019·8 cites·6 claims
- 1095US10426797B2Compositions and methods for treating cancer with anti-CD33 immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Oct 1, 2019·19 cites·10 claims
- 1193US11103533B2Compositions and methods for treating cancer with anti-CD38 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Aug 31, 2021·7 cites·13 claims
- 1293US10639329B2Method to treat cancer with engineered T-cellsLENTIGEN TECH INC·Filed 2016·Granted May 5, 2020·12 cites·6 claims
- 1393US10550179B2Compositions and methods for treating cancer with anti-mesothelin immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Feb 4, 2020·6 cites·18 claims
- 1493US6627442B1Methods for stable transduction of cells with hiv-derived viral vectorsVIRXSYS CORP·Filed 2000·Granted Sep 30, 2003·114 cites·30 claims
- 1592US11052112B2Compositions and methods for treating cancer with anti-BCMA immunotherapyLENTIGEN TECH INC·Filed 2020·Granted Jul 6, 2021·5 cites·9 claims
- 1692US10822412B2Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapyLENTIGENTECHNOLOGY INC·Filed 2019·Granted Nov 3, 2020·6 cites·14 claims
- 1789US11453712B2Compositions and methods for treating cancer with DuoCARsLENTIGEN TECH INC·Filed 2017·Granted Sep 27, 2022·2 cites·8 claims
- 1887US11453719B2Compositions and methods for treating cancer with anti-ROR1 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Sep 27, 2022·2 cites·19 claims
- 1987US6498033B1Lentiviral vectorsUNIV JOHNS HOPKINS MED·Filed 2000·Granted Dec 24, 2002·15 cites·10 claims
- 2087US2024043497A1Compositions and Methods for Treating Cancer with DuoCARsLENTIGEN TECH INC·Filed 2023·Application pending·0 cites
- 2187US2025367291A1Compositions and Methods for Treating Cancer with DuoCARsLENTIGEN TECH INC·Filed 2025·Application pending·0 cites
- 2286US11802142B2Compositions and methods for treating cancer with DuoCARsLENTIGEN TECH INC·Filed 2020·Granted Oct 31, 2023·1 cites·7 claims
- 2386US2024025962A1Compositions and methods for treating cancer with duocarsLENTIGEN TECH INC·Filed 2023·Application pending·0 cites
- 2485US10421810B2Chimeric antigen receptors and methods of useMILTENYI BIOTEC TECH INC·Filed 2016·Granted Sep 24, 2019·6 cites·19 claims
- 2585US6410257B1Methods to assay gene function with viral vectorsUNIV JOHNS HOPKINS MED·Filed 2000·Granted Jun 25, 2002·11 cites·51 claims
- 2684US10894819B2Compositions and methods for treating HIV/AIDS with immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Jan 19, 2021·2 cites·18 claims
- 2783US7572906B2Viral vectors and host cells and methods of making and using themUNIV JOHNS HOPKINS MED·Filed 2004·Granted Aug 11, 2009·5 cites·12 claims
- 2883US5888767AMethod of using a conditionally replicating viral vector to express a geneUNIV JOHNS HOPKINS MED·Filed 1997·Granted Mar 30, 1999·36 cites·14 claims
- 2982US11878052B2Compositions and methods for treating cancer with anti-CD22 immunotherapyLENTIGENTECHNOLOGY INC·Filed 2020·Granted Jan 23, 2024·1 cites·19 claims
- 3082US2022281946A1Compositions and Methods for Treating Cancer with DuoCARsLENTIGEN TECH INC·Filed 2022·Application pending·0 cites
- 3181US12365718B2Compositions and methods for treating cancer with DuoCARsLENTIGEN TECH INC·Filed 2021·Granted Jul 22, 2025·0 cites·8 claims
- 3281US11464801B2Compositions and methods for treating cancer with anti-CD33 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Oct 11, 2022·1 cites·15 claims
- 3381US6232120B1Methods to inhibit replication of infective virusUNIV JOHNS HOPKINS MED·Filed 1999·Granted May 15, 2001·35 cites·32 claims
- 3480US2025084166A1Compositions and Methods for Treating Cancer with Anti-CD19/CD22 ImmunotherapyLENTIGEN TECH INC·Filed 2024·Application pending·0 cites
- 3580US2024067724A1Compositions and Methods for Treating Cancer with Anti-CD19 ImmunotherapyLENTIGEN TECH INC·Filed 2023·Application pending·0 cites
- 3679US2024108706A1Compositions and Methods for Treating Cancer with Anti-CD22 ImmunotherapyLENTIGEN TECH INC·Filed 2023·Application pending·0 cites
- 3779US2024150773A1Chimeric Antigen Receptors and Methods of UseLENTIGEN TECH INC·Filed 2024·Application pending·0 cites
- 3879US2025090631A1Method to Treat Cancer with Engineered T-CellsLENTIGEN TECH INC·Filed 2024·Application pending·0 cites
- 3978US2024309102A1Compositions and Methods for Treating Cancer with Anti-CD123 ImmunotherapyLENTIGEN TECH INC·Filed 2024·Application pending·0 cites
- 4078US2024368256A1Compositions and methods for treating hiv/aids with immunotherapyLENTIGEN TECH INC·Filed 2024·Application pending·0 cites
- 4177US6835568B2Regulated nucleic acid expression systemVIRXSYS CORP·Filed 2001·Granted Dec 28, 2004·6 cites·19 claims
- 4277US2024034802A1Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapyLENTIGEN TECH INC·Filed 2023·Application pending·0 cites
- 4376US12371490B2Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapyLENTIGEN TECH INC·Filed 2022·Granted Jul 29, 2025·0 cites·27 claims
- 4476US11905515B2Chimeric antigen receptors and methods of useLENTIGEN TECH INC·Filed 2019·Granted Feb 20, 2024·0 cites·2 claims
- 4575US11708408B2Compositions and methods for treating cancer with anti-CD19 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Jul 25, 2023·0 cites·17 claims
- 4674US2023241103A1Compositions and Methods for Treating Cancer with Anti-CD33 ImmunotherapyLENTIGEN TECH INC·Filed 2022·Application pending·0 cites
- 4772US12037403B2Compositions and methods for treating cancer with anti-CD123 immunotherapyLENTIGEN TECH INC·Filed 2020·Granted Jul 16, 2024·0 cites·8 claims
- 4872US11680103B2Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Jun 20, 2023·0 cites·6 claims
- 4971US12391958B2Compositions and methods for treating cancer with anti-CD38 immunotherapyLENTIGEN TECH INC·Filed 2021·Granted Aug 19, 2025·0 cites·21 claims
- 5071US12391740B2Compositions and methods for treating cancer with anti-BCMA immunotherapyLENTIGEN TECH INC·Filed 2021·Granted Aug 19, 2025·0 cites·23 claims
Showing the top 50 of 79 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Boro Dropulic files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →